Cyclophosphamide

Generic Name: Cyclophosphamide

Brand Names: Procytox

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 50-18-0

Unique Ingredient Identifier: 6UXW23996M

Background: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication: Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma

Associated Therapies: -

Clinical Trials

Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas

Phase 1

Terminated

Conditions: High-grade B-cell Lymphoma
T-cell/Histocyte-rich Large B-cell Lymphoma
Diffuse Large B-Cell Lymphoma (DLBCL)
Germinal Center B-cell Type (GCB)
Burkitt Lymphoma

Interventions: Biological: Rituximab
Drug: Etoposide
Biological: Copanlisib
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vincristine
Drug: Prednisone
Diagnostic Test: ECHO
Diagnostic Test: EKG
Diagnostic Test: MRI Brain
Diagnostic Test: 18F-FDG - PET
Diagnostic Test: CT Scan
Procedure: Bone Marrow Aspiration
Procedure: Bone Marrow Biopsy
Diagnostic Test: Lumbar Puncture (LP)

First Posted Date: 2021-06-22

Last Posted Date: 2024-07-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 8

Registration Number: NCT04933617

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors

Phase 2

Active, not recruiting

Conditions: Ovarian Cancer

Interventions: Drug: Giredestrant
Drug: Inavolisib
Drug: Trastuzumab Emtansine
Drug: Cobimetinib
Drug: Atezolizumab
Drug: Ipatasertib
Drug: Paclitaxel
Drug: Bevacizumab
Drug: Abemaciclib
Drug: Palbociclib
Drug: Olaparib
Drug: Luteinizing Hormone-Releasing Hormone (LHRH) Agonists
Drug: Letrozole
Drug: Cyclophosphamide

First Posted Date: 2021-06-18

Last Posted Date: 2024-12-19

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 176

Registration Number: NCT04931342

Locations: 🇫🇷
CHU Besançon - Hôpital Jean Minjoz, Besançon Cedex, France
🇫🇷
Institut Bergonie; Oncologie, Bordeaux, France
🇫🇷
Centre Francois Baclesse; Oncologie, Caen, France

and more 51 locations

A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior Therapies

Phase 1

Terminated

Conditions: Advanced Triple Negative Breast Cancer

Interventions: Biological: N-803
Biological: PD-L1 t-haNK
Drug: Sacituzumab Govitecan-Hziy
Drug: Cyclophosphamide

First Posted Date: 2021-06-16

Last Posted Date: 2024-06-12

Lead Sponsor: ImmunityBio, Inc.

Target Recruit Count: 3

Registration Number: NCT04927884

Locations: 🇺🇸
Hoag Memorial Hospital, Newport Beach, California, United States

A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy

Phase 3

Active, not recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Bortezomib
Drug: Dexamethasone
Drug: Lenalidomide
Drug: Cilta-cel
Drug: Cyclophosphamide
Drug: Fludarabine

First Posted Date: 2021-06-11

Last Posted Date: 2024-12-06

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 650

Registration Number: NCT04923893

Locations: 🇺🇸
University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
🇺🇸
University of Kentucky, Lexington, Kentucky, United States
🇺🇸
Norton Cancer Institute, Louisville, Kentucky, United States

and more 132 locations

Efficacy and Safety of Lenalidomide Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma

Phase 2

Recruiting

Conditions: CHOP
Peripheral T-Cell Lymphoma
Lenalidomide

Interventions: Drug: Lenalidomide
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vincristine
Drug: Prednisone

First Posted Date: 2021-06-10

Last Posted Date: 2022-11-07

Lead Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University

Target Recruit Count: 289

Registration Number: NCT04922567

Locations: 🇨🇳
2nd Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China

A Multicentre, Parallel Arm, Open-label Trial of Frontline R-CHOP/Pola-RCHP and Glofitamab in Younger, Higher Risk Patients With Diffuse Large B Cell Lymphoma (DLBCL)

Phase 1

Active, not recruiting

Conditions: Diffuse Large B Cell Lymphoma
High-grade B-cell Lymphoma

Interventions: Drug: Rituximab
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vincristine
Drug: Prednisolone
Drug: Glofitamab
Drug: Polatuzumab vedotin

First Posted Date: 2021-06-07

Last Posted Date: 2024-08-12

Lead Sponsor: Peter MacCallum Cancer Centre, Australia

Target Recruit Count: 80

Registration Number: NCT04914741

Locations: 🇦🇺
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
🇦🇺
St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia
🇦🇺
Alfred Hospital, Melbourne, Victoria, Australia

and more 12 locations

ImmPACT Expanded Multiple Antigen Specific Endogenously Derived T Cells (MASE-T) to Patients With Metastatic Melanoma

Phase 1

Terminated

Conditions: Malignant Melanoma

Interventions: Drug: Cyclophosphamide
Drug: Fludarabine Phosphate
Biological: Multiple Antigen Specific Endogenously derived T cells
Drug: Pembrolizumab

First Posted Date: 2021-05-27

Last Posted Date: 2024-07-19

Lead Sponsor: Inge Marie Svane

Target Recruit Count: 6

Registration Number: NCT04904185

Locations: 🇩🇰
National Center for Cancer Immune Therapy (CCIT-DK), Herlev, Denmark

HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide

Phase 2

Recruiting

Conditions: Chronic Myelogenous Leukemia
Mixed Phenotype Acute Leukemia
Acute Leukemia
Acute Lymphoblastic Leukemia
Chronic Lymphocytic Leukemia
Acute Myelogenous Leukemia
Myelodysplastic Syndromes
Lymphoma

Interventions: Drug: Busulfan
Radiation: Total-body irradiation
Drug: Melphalan
Drug: Cyclophosphamide
Drug: Fludarabine
Procedure: PBSC Hematopoietic Stem Cell Transplantation (HSCT)
Procedure: Bone Marrow Hematopoietic Stem Cell Transplantation
Drug: Post-transplant Cyclophosphamide
Drug: Mesna
Drug: Tacrolimus
Drug: Mycophenolate Mofetil
Other: Patient-Reported Outcomes

First Posted Date: 2021-05-27

Last Posted Date: 2024-05-23

Lead Sponsor: Center for International Blood and Marrow Transplant Research

Target Recruit Count: 300

Registration Number: NCT04904588

Locations: 🇺🇸
Levine Cancer Institute, Charlotte, North Carolina, United States
🇺🇸
Ohio State Medical Center, James Cancer Center, Columbus, Ohio, United States
🇺🇸
City of Hope National Medical Center, Duarte, California, United States

and more 37 locations

Zanubrutinib Combined With R-CHOP in Newly-diagnosed Intravascular Large B-cell Lymphoma

Phase 2

Recruiting

Conditions: Intravascular Large B-Cell Lymphoma

Interventions: Drug: Zanubrutinib
Drug: Rituximab
Drug: Cyclophosphamide
Drug: Epirubicin
Drug: Vindesine
Drug: Prednisone

First Posted Date: 2021-05-24

Last Posted Date: 2021-05-24

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 20

Registration Number: NCT04899570

Locations: 🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China

B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)

Phase 1

Recruiting

Conditions: Osteosarcoma
Neuroblastoma
Desmoplastic Small Round Cell Tumor
Malignant Peripheral Nerve Sheath Tumors
Soft Tissue Sarcoma
Melanoma
Ewing Sarcoma
Adrenocortical Cancer
Rhabdoid Tumor
Pediatric Solid Tumor

Interventions: Drug: Fludarabine
Drug: Cyclophosphamide
Drug: MESNA
Drug: B7-H3 CAR T cells

First Posted Date: 2021-05-21

Last Posted Date: 2024-08-19

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 32

Registration Number: NCT04897321

Locations: 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy